Distinguished in Lung Adenocarcinoma

Dr. Vinicius Ernani

Hematology | Oncology
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
18 Years of Experience
Distinguished in Lung Adenocarcinoma
AZ - Cancer
5777 E Mayo Blvd, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vinicius Ernani is a Hematologist and an Oncologist in Phoenix, Arizona. Dr. Ernani has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Lung Adenocarcinoma.

Graduate Year
2008
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NE
Hospital Affiliations
Mayo Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

AZ - Cancer
5777 E Mayo Blvd, Phoenix, AZ 85054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: April 23, 2025
Intervention Type: Drug, Device
Study Phase: Phase 2
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase I Study of Durvalumab (MEDI4736) Plus Tremelimumab in Combination With Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2
A Phase I Study of Durvalumab (MEDI4736) Plus Tremelimumab in Combination With Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Combination product
Study Drugs: Durvalumab+Tremelimumab+Carboplatin+Etoposide, Durvalumab+Carboplatin+Etoposide
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

49 Total Publications

Adjuvant immune checkpoint inhibitors in early-stage non-small cell lung cancer: insights from a systematic review and meta-analysis.
Adjuvant immune checkpoint inhibitors in early-stage non-small cell lung cancer: insights from a systematic review and meta-analysis.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: May 11, 2025
Similar Doctors
Jason Niu
Distinguished in Lung Adenocarcinoma
Dr. Jason Niu
Oncology | Hematology | Otolaryngology
Distinguished in Lung Adenocarcinoma
Dr. Jason Niu
Oncology | Hematology | Otolaryngology

Banner MD Anderson Cancer Center At Banner Gateway Medical Center

2946 East Banner Gateway Drive, 
Gilbert, AZ 
 (24.0 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy running, playing tennis and gardening. Dr. Niu is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

Distinguished in Lung Adenocarcinoma
Dr. Justin Goldfarb
Hematology | Oncology
Distinguished in Lung Adenocarcinoma
Dr. Justin Goldfarb
Hematology | Oncology

Arizona Center For Hematology And Oncology PLC

5750 W Thunderbird Rd Ste C300, 
Glendale, AZ 
 (12.9 miles away)
602-938-2848
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Justin Goldfarb is a Hematologist and an Oncologist in Glendale, Arizona. Dr. Goldfarb is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, and Pleuropulmonary Blastoma.

Distinguished in Lung Adenocarcinoma
Dr. Panayiotis Savvides
Hematology | Oncology
Distinguished in Lung Adenocarcinoma
Dr. Panayiotis Savvides
Hematology | Oncology

DH Cancer Institute At St. Joseph's Outpatient Pharmacy

625 N 6th St, 
Phoenix, AZ 
 (15.5 miles away)
602-406-8222
Languages Spoken:
English
See accepted insurances

Panayiotis Savvides is a Hematologist and an Oncologist in Phoenix, Arizona. Dr. Savvides is rated as a Distinguished provider by MediFind in the treatment of Lung Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ernani's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile